For foreign Emerging Stock Board enterprises, ”*- country of incorporation” indicates stocks without par value or with par value other than NT$10, and ”- country of incorporation” indicates stocks with par value of NT$10 per share.
|
Basic information |
Chairman |
President |
Spokesperson |
Telephone |
Address |
ESM Registration Date |
Chen,Chi-Chuan |
Her, Jeng-Horng |
Her, Jeng-Horng |
02-26532886 |
11F-2,No508,Sec7,Zhongxao E RdTaipei, Taiwan |
2023/07/14 |
Industrycategory |
Key businesses |
Biotechnology and Medical Care |
Over the last 20 years, the growth of biotherapeutic antibodies, has had a dramatic impact on many areas of medicine, including infectious, immune-mediated, and respiratory diseases, as well as hematology and oncology. APBio is currently developing fully-human,mono- and bi-specific antibodies with novel mechanisms of action to fulfill unmet medical needs.
Combining our integrated protein engineering and antibody technology, we have produced a portfolio of biotherapeutic leads & bi-specific antibodies to treat serious medical conditions with a primary clinical focus on oncology. With mechanism-based drug design focusing on disease-specific targets, we are aiming to provide patients with medicines that are safe, efficacious and cost-effective. We believe that the biotherapeutics developed this way will offer important clinical and economic advantages, making these protein drugs better choices for the patients. |
Financial data |
Cash flows statement
| Item
|
|
|
Amount(NTD, in thousands) |
Cash flows from operating activities |
|
|
Cash flows from investing activities |
|
|
Cash flows from financing activities |
|
|
Consolidated/Individual balance sheet
|
Current assets |
|
|
Non-current assets |
|
|
Total assets |
|
|
Current liabilities |
|
|
Non-current liabilities |
|
|
Total liabilities |
|
|
Share capital |
|
|
Capital surplus |
|
|
Retained earnings |
|
|
Other equity interest |
|
|
Treasury shares |
|
|
Total equity attributable to owners of parent |
|
|
Non-controlling interests |
|
|
Total equity |
|
|
Book Value per share(NT$) |
|
|
Consolidated/Individual profit and loss statement |
Operating revenue |
|
|
Operating costs |
|
|
Gross profit from operations |
|
|
Operating expenses |
|
|
Net other income (expenses) |
|
|
Net operating income |
|
|
Non-operating income and expenses |
|
|
Profit before tax |
|
|
Tax expense |
|
|
Profit from continuing operations |
|
|
Profit from discontinued operations |
|
|
Profit |
|
|
Other comprehensive income |
|
|
Comprehensive income |
|
|
Basic earnings per share |
|
|
Auditor's report on latest financial statements: auditor's report:
|
Investors may find more detailed information on the company by visiting the Market Observation Post System.。
|
The information disclosed here concerning foreign enterprises consists of amounts provided in consolidated financial statements.
|